Industry Groups Challenge Readiness of ICER’s Value Framework

Healthcare is all about making decisions. Who to treat? When to treat? How to treat? How long to treat? How much to spend to treat? The list goes on and on. Fortunately, great strides have been made in healthcare decision… Continue Reading

Good, Bad, or Indifferent on Drug Pricing: A Value Benchmark Approach for Newly Launched Drugs in the United States.

Hardly a day goes by without a new article being published in the mainstream press or a medical journal discussing drug pricing.  The cost of drugs is a hot potato topic at medical meetings, pharma conference rooms, government hearings, and… Continue Reading

Integrating Big Data: How HealthCore is using Research to Improve Care, Safety, and Outcomes.

Companies are striving to advance beyond the buzzword of Big Data to delivering real, actionable results that change the way our healthcare system works.  The power to access and analyze these enormous data sets, and then develop insights that can… Continue Reading

Real-World Evidence Studies: Checking it Once, Checking it Twice…

By now, either through posts on this tHEORetically Speaking blog, the official blog of HealthEconomics.Com, or through your own personal experience, it is apparent that real world evidence (RWE) is a hefty subject to tackle. Synthesizing evidence into something meaningful… Continue Reading

Achieving Market Access in India – Are You Hitting the Mark? An Interview with Marksman Healthcare Solutions CEO Dr. Amit Dang

It’s well-accepted that the Indian pharmaceuticals market cannot be ignored.  India will be one of the top 10 sales markets by 2020, fueled by the rapid growth in its population and economy.  Commensurately, India is experiencing expansion within its middle-class… Continue Reading